Here’s to why Indaptus Therapeutics Inc. (INDP) gains during current market trading session?

AVGR Stock
AVGR Stock

Indaptus Therapeutics Inc. (NASDAQ: INDP) gains by 237.41% in the current market trading session. INDP stock has evolved from more than a century of immunotherapy advances. The company’s approach is based on the hypothesis that efficient activation of both innate and adaptive immune cells and associated anti-tumor and anti-viral immune responses will require a multi-targeted package of immune system activating signals that can be administered safely intravenously.

INDP stock’ Current Update

The United States Patent and Trademark Office has given a notice of allowance for claims pertaining to Indaptus Therapeutics’ platform technology, according to INDP. The patent, titled “Methods of Treatment of Infections Using Bacteria” (Application No. 16/584,644), covers the use of the Company’s platform technology alone or in conjunction with standard of care for the cure and inhibition of hepatitis B virus (HBV) and human immunodeficiency virus (HIV) infections.

Top 5 Undervalued Stocks To Own In 2023

Microchip Maker Releases "World's Most Powerful Data Center CPU". It could allow the company who manufactures it to lead the industry as the global microchip shortage continues into the coming year. We've put together a free research report that explains all the details. Not only will you find out why analysts believe this chip manufacturer could lead the pack, you will also discover four more potential winners for the coming year.

Click here to download your Free Research Report…


The Indaptus pipeline is based on the idea that extremely effective anti-tumor or anti-viral immunotherapy will necessitate the secure activation of both innate and adaptive immunity in tumours, infection sites, and immune organs. As well as it is believed that this could be accomplished with a multi-targeted package of bacterial immune system activators in the form of attenuated, killed, and intact non-pathogenic.


In a pre-clinical model of chronic hepatitis B infection, single-agent treatments developed from the Indaptus platform exhibited considerably broader action than the quality of care treatment, as well as single-agent activity against chronic HIV infection in a pre-clinical humanised mouse model.

  • Michael Newman, Founder and Chief Scientific Officer of Indaptus Therapeutics said that they are excited to add to their growing patent portfolio, and this notice of allowance adds to the confirmation of their Indaptus platform technology’s innovative approach to viral infections.
  • Jeffrey Meckler, Chief Executive Officer of Indaptus Therapeutics added that this notice of allowance offers them the freedom to firmly explore their viral illness technology and/or work with others to further develop it.


Please enter your comment!
Please enter your name here